Call it the shot heard around the wellness world. A black-market peptide economy worth up to $3B is on the cusp of going legal, thanks to a peptide-friendly White House and an upcoming FDA advisory panel meeting in late July. The industry is now nearing its largest inflection point yet.
Riding the wave: The peptide black market exploded as consumers who discovered GLP-1 weight-loss drugs went looking for more. The FDA’s Pharmacy Compounding Advisory Committee will soon decide whether seven peptides can be legally compounded. Health Secretary Robert F. Kennedy Jr. says the move would help replace an underground market with regulated access. Telehealth companies, compounding pharmacies, and investors are hoping to capture the boom.
- US Customs logged $328M in peptide active pharmaceutical ingredient imports in the first nine months of 2025, more than double the prior year’s pace.
- Testing lab Janoshik Analytical saw peptide sample volumes surge 1,200% from 2023 to 2025, indicating how quickly underground demand has grown.
Contenders vs. Complications
The opportunity looks sizable, but it’s highly sensitive to regulation. Leerink Partners projects the telehealth peptide market could reach $2.2B by 2027, with Hims & Hers Health potentially capturing ~$440M. In a more conservative scenario where providers prescribe fewer peptides, the firm cuts its market estimate to $1.1B and Hims’ revenue opportunity to ~$220M, underscoring how wide the range of outcomes remains. The field is quickly filling up.
- LifeMD is also well-positioned to benefit as broader compounding expands telehealth access to peptide therapies.
- The Precision Peptide Company is ramping up commercialization through a marketing partnership with Mixed Martial Arts Group.
The regulatory tightrope: The FDA recently issued 25 warning letters to telehealth companies over misleading claims about compounded GLP-1 drugs, showing that legalization won't mean a free-for-all. Supply chains still rely heavily on Chinese manufacturers, and scaling production will take time to establish regulatory-compliant sourcing. The peptide race has begun, but compliance may prove to be the ultimate performance enhancer.
